GET THE APP

The role of the microbiome in COPD
..

Pulmonary & Respiratory Medicine

ISSN: 2161-105X

Open Access

The role of the microbiome in COPD


3rd International Conference on Chronic Obstructive Pulmonary Disease

July 11-12, 2016 Brisbane, Australia

Phil Hansbro

University of Newcastle, Australia
Hunter Medical Research Institute, Australia

Scientific Tracks Abstracts: J Pulm Respir Med

Abstract :

Recent technical advances have enabled the assessment of entire microbiomes in tissues. Th is had led to the elucidation of their roles in health and disease. Until recently the lower respiratory tract was thought to be sterile but microbiome studies have shown this not to be the case and that there is a core lung microbiome. Alterations in the microbiome indicate and may be causal in disease. In dysbiosis commensals are displaced by pathogens that drive infl ammation and infl ammatory diseases including the in the respiratory tract. It is now established that there is infectious and infl ammatory cross talk between the lung and gut and so changes in gut microbiomes may also be involved in respiratory disease potentially through the induction of systemic infl ammation. Th e current state of the fi eld in COPD will be assessed and new data from our lab on the role of changes in the gut microbiome in this disease will be presented.

Biography :

Phil Hansbro holds a tenured Chair of Immunology & Microbiology at the University of Newcastle and a National Health and Medical Research Council (NHMRC) of Australia. He has established and leads a team that investigates the pathogenesis of infectious and respiratory diseases including asthma, COPD and recently lung cancer. He has extensive expertise in the development and utilization of mouse models that recapitulate the hallmark features of human disease and complimentary human studies using state of the art facilities. He has developed unique short-term mouse models of severe, steroid-resistant asthma, COPD and lung cancer. He has established expertise and techniques in assessing infl ammation and pathophysiology in experimental infections, asthma, COPD and lung cancer. His group routinely performs analysis of infl ammatory cell infl ux and cytokine/chemokine levels assess remodeling in terms of mucus secreting cell hyperplasia, collagen levels/deposition/fi brosis and epithelial thickening and emphysema. His group has expertise in assessing infl ammatory processes including infl ammasomes, microRNAs, microbiomes, epigenetic, oxidative stress, etc, in these systems.

Email: philip.hansbro@newcastle.edu.au

Google Scholar citation report
Citations: 1690

Pulmonary & Respiratory Medicine received 1690 citations as per Google Scholar report

Pulmonary & Respiratory Medicine peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward